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Thrombospondin 1 is expressed by proliferating mesangial cells and is
up-regulated by PDGF and bFGF in viva. Thrombospondin I has been
shown to be linked to PDGF-mediated mesangial cell proliferation and
migration in vitro, but little is known regarding its expression or regulation
in glomerular disease. Experimental mesangial proliferative nephritis was
induced in rats by injection of anti-Thyl antibody. Mesangial cell prolif-
eration was associated with de novo expression of thrombospondin 1
mRNA (detected by Northern blot and in situ hybridization) and protein
(by Western blot and immunostaining). Although some thrombospondin I
was expressed by platelets and macrophages, double labeling showed that
most thrombospondin 1 mRNA and protein were expressed by prolifer-
ating a-actin-positive mesangial cells. Thrombospondin 1 expression in
anti-Thyl nephritis was complement-dependent and could he reduced by
treatment with anti-PDGF or anti-bFGF antibodies. Thrombospondin 1
could also be induced in normal rats by infusion of PDGF and in rats
which were primed with low dose anti-Thy 1 antibody by infusion of PDGF
or bFGF. Thus, this study demonstrates that proliferating mesangial cells
express thrombospondin I de novo in disease and that thrombospondin I
expression in vivo is regulated by PDGF and bFGF.
Thrombospondin 1 (TSP1) is a homotrimeric, disulfide-bonded,
arginine-glycine-aspartic acid (RGD) containing extracellular gly-
coprotein of 450 kD, that is a member of a small family of related
proteins (TSPI to 5), encoded by different genes [1]. TSPI was
first characterized as a major component of the releasate of
thrombin-activated platelets [2—4]. Since its initial description,
TSP1 has been found to be expressed by a wide variety of cells,
including fibroblasts, endothelial cells (EC), vascular smooth
muscle cells (VSMC), mesangial cells (MC), macrophages/mono-
cytes, epithelial cells and neoplastic cells [fl. In vitro studies have
shown that TSP1 can specifically interact with several extracellular
matrix proteins, including types Ito V collagen [5], fibronectin [6],
SPARC [7], heparan sulfate proteoglycan (HSPG) [8], decorin
[9], and TGF-f3 [10]. Numerous in vitro studies in various cell types
have shown that TSP1 is capable of multiple and divergent
functions. TSPI is important in platelet aggregation [11, 12],
platelet-monocyte [13] and monocyte-endothelial cell adhesion
[14], and migration of neutrophils [15] and monocytes [14]. TSP1
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also supports phagocytic clearance of senescent neutrophils by
macrophages [16J.
Several studies suggest that TSP1 may be important in prolif-
eration and migration of mesenchymal cells, and that this may
involve an interaction with platelet-derived growth factor
(PDGF). TSP1 mediates vascular smooth muscle cell (VSMC)
and glomerular MC proliferation, adhesion and migration in vitro
[17, 18]. TSP1-mediated proliferation of MC can be inhibited by
anti-PDGF antibodies [19]. Likewise, the migratory effect of
PDGF on VSMC can be abolished by anti-TSP1 antibody [18].
TSPI also stimulates PDGF expression in MC [19], and PDGF
stimulates TSPI expression in VSMC and MC [201. This suggests
that TSPI may have an autocrine/paracrine role in PDGF-
mediated VSMC and MC proliferation and migration in vitro.
We now present the first in vivo evidence that TSP1 is intricately
linked to MC proliferation, and that its expression is regulated by
PDGF and basic fibroblast growth factor (bFGF). Following
criteria modeled after Koch's postulates [21], we demonstrate
that: (a) TSP1 mRNA is induced by PDGF and bFGF in rat MC
in vitro; (b) TSP1 is expressed by MC in PDGF- and bFGF-
dependent experimental glomerulonephritis and correlates highly
with cell proliferation; (c) infusion of PDGF or bFGF induces
TSP I protein expression by MC in vivo; and (d) blocking PDGF or
bFGF with neutralizing antibodies reduces TSP1 expression in
experimental nephritis. The data presented suggest that TSP1 is a
proliferative phenotypic marker for MC in vivo, and suggest a
regulatory interaction between TSP1 and PDGF and bFGF in
mesenchymal cell injury.
Methods
Experiments with cultured rat mesangial cells
Rat MC were prepared from collagenase-digested glomeruli,
characterized and maintained as described previously [22]. After
reaching subconfluency, MC were growth-arrested for 72 hours in
RPMI-medium (Irvine Scientific, Santa Ana, CA, USA). Medium
was then replaced with RPMI-medium with or without 5 ng/ml
PDGF-BB (gift from C. Hart, Zymogenetics, Seattle, WA, USA)
or 10 ng/ml bFGF (provided by Synergen, Boulder, CO, USA).
Total RNA was extracted after three and six hours and Northern
analysis performed as described below. This experiment was
repeated three times. The growth-arrested state of the MC was
confirmed by measuring the [1H] thymidine (DuPont NEN,
Boston, MA, USA) uptake of the MC during the last 18 hours of
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growth arrest in comparison to MC with RPMI-medium and
different concentrations of fetal calf serum (FCS) as described by
Floege et a! [22].
In vivo disease model and experimental protocol
Goat anti-rat thymocyte plasma was prepared as described
previously [23]. Experimental mesangial proliferative nephritis
was induced in 180 to 220 g male Wistar rats (Simonsen Labora-
tories, Gilroy, CA, USA) by intravenous injection of 0.4 cc
anti-thymocyte plasma per 100 g body wt. Rats were sacrificed and
renal biopsies and total glomerular RNA obtained at days 2, 5, 7,
and 14 (N = 6 to 9 per group). Six additional rats were also
complement-depleted for five days with cobra venom factor
(CVF) (Diamedics Corp., Miami, FL, USA). In these rats, C3
levels were measured by radial immunodiffusion [23] and values of
< 10% were maintained throughout the study period. Six normal
rats (day 0) served as controls. Three additional rats, used either
as normal controls or injected with anti-thymocyte plasma, were
sacrificed at day 5, and cellular protein was extracted from
isolated glomeruli for immunoblotting with anti-TSP1 antibody
[271.
To determine if TSP1 is induced by PDGF or bFGF in vivo, we
also studied TSP1 protein expression in normal and low dose
anti-Thyl rats that had received a seven day intravenous infusion
of either PDGF-BB or bFGF, as described by Floege et al [241.
Rats were sacrificed at days 2, 4, and 7 after starting the cytokine
infusion.
TSP1 protein and mRNA expression were examined in rats with
anti-Thyl nephritis, which had also received neutralizing anti-
PDGF antibody as previously described [25].
Finally, the effect of neutralizing anti-bFGF antibody on TSPI
protein expression in the anti-Thyl model was investigated. Goat
anti-human recombinant bFGF IgG (gift of M. Reidy) or control
goat IgG was given (30 mg i.p. and 30 mg i.v.) to male Wistar rats
(170 to 190 g) 30 minutes prior to injection of anti-Thyl plasma
and renal biopsies were obtained at days 2, 4, and 7. The
anti-bFGF IgG inhibited the proliferative effect of bFGF on NIH
3T3 cells in vitro and also reduced the initial smooth muscle cell
replication in rats following carotid angioplasty [M. Reidy, per-
sonal communication, and 26].
Renal moipholo and immunohistochemist..y
Renal biopsies were fixed in methyl Carnoy's solution and
embedded in paraffin [27]. Indirect immunoperoxidase staining of
4 m sections was performed as described previously [27] using
the following primary antibodies: murine monoclonal antibodies
TSP A4.i (1gM) and TSP A6.1 (IgG1) (provided by Dr. V. Dixit
[28]), an affinity-purified rabbit polyclonal antibody against hu-
man platelet TSP1 [29], a murine monoclonal 1gM antibody
against the proliferating cell nuclear antigen (PCNA) (19A2;
Coulter Immunology, Hialeah, FL, USA), a murine monoclonal
IgG1 antibody, ED-i, to a cytoplasmic antigen present in mono-
cytes, macrophages and dendritic cells (Bioproducts for Science,
Inc., Indianapolis, IN, USA), a murine monoclonal IgG antibody,
PGF-007, to a 25-amino acid peptide of the human PDGF-B
chain (Mochida Pharmaceutical, Tokyo, Japan) and a monoclonal
IgG2 antibody against a-sm actin (Sigma Chemical Co, St. Louis,
MO, USA).
The specifity of the monoclonal anti-TSP antibody, TSP A6.1,
and the rabbit polyclonal affinity-purified anti-TSP1 antibody was
tested by Western analysis of TSPI from purified human platelets
and murine TSP2 expressed in baculovirus-infected SF9 cells. No
cross reactivity to TSP2 was seen with the affinity-purified poly-
clonal antibody, and there was very little cross reactivity with TSP
A6.1. Negative controls for immunostaining included either de-
leting the primary antibody or substitution of the primary anti-
body with equivalent concentrations of an irrelevant murine
monoclonal antibody or preimmune rabbit IgG. For each biopsy,
20 to 70 glomerular cross sections were evaluated in a blind
fashion. Glomerular expression of TSP1 and PDGF was graded
semiquantitatively [22, 24] and reflected changes in the area and
intensity of mesangial staining: 0, very weak or absent staining;
1+, weak staining with < 25% of the glomerular tuft showing
focally increased staining; 2+, 25 to 49% of the glomerular tuft
with focally increased staining; 3+, 50 to 75% of the glomerular
tuft demonstrating increased staining; 4+, > 75% of the glomer-
ular tuft stained strongly. Mean values per biopsy were calculated
for the number of proliferating cells per cross section.
Immunohistochemical double staining
To determine the cell type expressing TSP1, double immuno-
staining for PCNA and TSP1 was performed using an indirect
immunoperoxidase technique. Both primary antibodies (PCNA
and TSP A6.1) were incubated overnight at 4°C, followed sequen-
tially by peroxidase-conjugated rat anti-mouse 1gM (Zymed)
antibody, diaminobenzidine (DAB; Sigma) with nickel chloride,
biotinylated rabbit anti-mouse IgG1 (Zymed, San Francisco, CA,
USA), avidin D peroxidase, and finally DAB without nickel
chloride. For double staining of TSP1 and macrophages, TSP
A4.i and ED-i antibodies were employed and the equivalent
protocol was used. In order to identify the TSP1-positive cells as
MC, either the polyclona! rabbit TSP1 or the monoclonal TSP
A6.i antibody was incubated with a-sm actin antibody (a marker
of activated MC) [301 and the same protocol followed.
Double staining for a-sm actin and TSPI was also performed on
4 rm sections of methyl Carnoy's fixed, paraffin-embedded tissue
using an immunofluorescent system. Following the primary anti-
bodies, biotinylated goat anti-rabbit IgG (Vector, Burlingame,
CA, USA), Texas red-conjugated avidin D (Vector) and FITC-
conjugated anti-mouse IgG2 (Cappel) antibody were applied in
the order listed. The controls for all double staining procedures
consisted of replacing either one of the primary antibodies with an
irrelevant mouse monoclonal antibody or preimmune rabbit IgG.
Combination of [1HJ thymidine labeling and
immunocytochemistiy
Two rats at day 5 (control and anti-Thyl disease) were [3H]
thymidine (6.7 Ci/mmol, 1 mCi/ml)-labeled by intraperitoneal
injections (50 jiCi/1 00 g body wt) 17, 9, and I hours before death
[31]. Tissue was fixed in methyl Carnoy's and paraffin-embedded.
Immunoperoxidase staining for TSPI and double staining for
TSP IIPCNA was performed as described above. Sections were
then dehydrated, air dried, dipped in NTB 2 emulsion (Kodak,
Rochester, NY, USA), stored in the dark at 4°C for three weeks,
developed and counterstained.
Immunoblotting of TSP]
Kidneys were isolated, perfused in situ with 50 ml ice cold PBS
containing 1 m each of proteinase inhibitors [Pefabloc (Center
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Fig. 1. Northern analysis of total RNA from growth-arrested, bFGF or
PDGF-b'B-stjmulated after () 3 hr or ) 6 hr rat MCs in culture. A. A
representative Northern blot for TSP1 mRNA and detection of corre-
sponding 28S RNA. B. The quantification of three independent tissue
culture experiments, normalized to 28S RNA. Data are mean so, N =
3 each. *p < 0.01 versus growth arrested MC (controls).
Chemicals, Standford, CT, USA), Pepstatin (Sigma), Leupeptin
(Sigma), Antipain (Sigma)], removed, the cortex separated, and
glomeruli isolated in the presence of proteinase inhibitors. Iso-
lated glomeruli were counted (3 aliquots each), lysed in 2 X
Lammli-sample buffer at room temperature (1 .tl buffer per 20
glomeruli) and the protein concentration was determined with the
DC protein assay (Bio-Rad Laboratories, Richmond, CA, USA).
The samples were either reduced with 5% /3-mercaptoethanol
(Sigma) or used unreduced, boiled for five minutes and centri-
fuged for five minutes at 11,600 x g. Protein extracted from 300
glomeruli was loaded per lane and electrophoresed through a 5%
stacking and 7% separating SDS-PAGE gel [32]. Proteins were
transferred to nitrocellulose filters by electroblotting [33], and
subsequently incubated with TSP A6.1 antibody, followed by an
alkaline phosphatase-conjugated anti-mouse IgG antibody (Pro-
mega, Madison, WI, USA) and BCIP/NBT.
Isolation and characterization of a 379 bp fragment of the rat
TSP1 cDNA
Since the rat sequence is unknown, mouse and human se-
quences of full length TSP1 cDNAs were aligned and homologous
regions were identified for potential primer pairs. Human Se-
Fig. 2. Northern analysis of glomendar RNA from normal (day 0) and
anti-Thy] diseased rats on days 2, 5, 7, and 14 for TSP] mRNA. A. A typical
Northern blot for TSP1 mRNA and corresponding 28S RNA. B. The
quantification of three independent glomerular RNA preparations, nor-
malized to 28S RNA. Data are mean so, N = 3 each. *p < 0.01 versus
day 0 (normal) rats.
quences were analyzed for PCR primers using the computer
program PCRPLAN (Intelligenetics, Palo Alto, CA, USA). The
following primers were selected, synthesized (Genset, San Diego,
CA, USA) and used to PCR-amplify cDNA which was reverse
transcribed from rat glomerular RNA: plus strand from bases
2938-2957, minus strand from bases 3293-3316 of hTSP1 coding
region cDNA (accession number X04665). A single DNA frag-
ment was amplified, and it was the expected size. It was purified
with the SpinBind-system (FMC, Rockland, ME, USA), cloned
into pT7Blue T-Vector (Novagen, Madison, WI, USA) and
subcloned into Bluescript SK (Stratagene, La Jolla, CA, USA).
The isolated fragment, when used as a probe for Northern
analysis, hybridized to the expected transcript size of 6.0 kb in a
variety of RNA samples from different cells and tissues (MC,
VSMC, isolated glomeruli), and did not cross react with TSP2
mRNA (using day 17 mouse embryo heart tissue, in which TSP2
mRNA is prominent). Hybridization was identical to that ob-
served with the human TSP1 probe, but sensitivity was dramati-
cally increased. Nucleotide sequence analysis of the isolated
fragment revealed 90% identity to the human TSP1 coding region
from base 2958-3292.
Preparation of glomerular RNA and Northern analysis
Total RNA was extracted from cultured MC or from three
separate glomerular preparations with RNAzol B (Cinna/Biotecx
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Laboratories, Friendswood, TX, USA) followed by LICI precipi-
tation [22]. Either 15 jg of denatured glomerular RNA or 10 jg
of cultured cell RNA per lane were electrophoresed through a 3%
formaldehyde, 1% agarose gel and transferred to a nylon mem-
brane (Hybond N+, Amersham) as previously described [30]. A
1.3 kb fragment of human eDNA [34] or the newly isolated 379 bp
fragment of rat TSP1 cDNA were radiolabeled with [32p] dCTP
(10 mCi/mi; New England Nuclear, Boston, MA) by random
primer extension. Membranes were prehybridized for 20 minutes,
hybridized with 2 X 106 cpm probe/ml for one to two hours at
68°C in Quickhyb solution (Stratagene, La Jolla, CA, USA) and
washed with 0.1 >< SSPE, 0.1% SDS twice for 30 minutes at 63°C
[30]. Signal intensity of Northern blots was determined by Phos-
pho-Imager analysis (Molecular Dynamics, Sunnyvale, CA,
USA) and normalized to 28 S ribosomal RNA (reprobed with a
bovine 280 bp eDNA probe provided by Drs, L. Iruela-Arispe and
H. Sage, University of Washington, Seattle, WA, USA). All
Northern blots were repeated at least three times with RNA from
different tissue culture experiments or different sets of animals.
In situ hybridization for TSPJ mRNA
TSP1 mRNA was detected by in situ hybridization on formalin-
fixed tissue using 35S-labeled anti-sense and sense-RNA probes to
human TSP1 [34] and rat TSP1 (as described above). Hybridiza-
tion was performed using a protocol of Wilcox et at [35]. After
developing, sections were counterstained with toluidine blue,
dehydrated and coverslipped. Quantitation of in situ hybridization
was done under brightfleld and darkfleld illumination using the
same scoring system as for immunohistochemistry.
Combined immunohistochemistty and in situ hybridization
Immunoperoxidase staining for ci-sm actin was performed at a
two- to threefold higher antibody concentration than described
above, under RNAse-free conditions and with the addition of 180
U/mi RNasin (Promega) to the primary and secondary antibodies
and avidin D. In situ hybridization for TSP1 mRNA was per-
formed immediately afterwards using the previously described
protocol. Immunohistochemistry for ED-i, as described earlier,
was done after the usual procedure for in situ hybridization of
TSP 1, including all the posthybridization washes. After the DAB
reaction, slides were rinsed in tap water, dehydrated in ethanol
(70% to 100%), air dried and dipped in NTB 2 emulsion.
Statistical analysis
All values are expressed as mean 5D. Statistical significance
(defined as P < 0.05) was evaluated using the Student's t test or
one way analysis of variance with modified t-tests performed using
the Bonferroni method.
Results
TSP1 mRNA is induced in mesangial cells in culture in response
Fig. 3. In situ hybridization for TSP] mRNA in glomeruli of normal (day 0) to PDGF and bFGF
and diseased rats (day 5). Positive hybridization is indicated by white grains
in the darkfietd (A and C) and by the dark grains in the brightfield (B and Incubation of growth-arrested MC with PDGF-BB or bFGF
D) photomicrographs. In normal rats glomeruli (A B) were usually
negative for TSP1 mRNA. At the peak of MC proliferation (C, D) TSPI stimulated TSP1 mRNA expression in rat MC at three hours (2-
mRNA is strikingly increased in a pattern consistent with a mesangial to 4-fold) and peaked at six hours (4- to 7-fold) in comparison to
distribution, growth arrested cells (N = 3, Fig. 1).
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Fig. 4. Immunostaining for TSP] protein in normal and diseased glomendi.
In glomeruli from normal rats TSP1 protein is usually absent (A). At day
2 of anti-Thyl disease TSP1-positive platelets and glomerular cells close to
the juxtaglomerular apparatus can be identified (B). At day 5 maximal
TSP1 protein expression can be identified in a typical mesangial pattern
(C) and is highly suggestive of extracellular deposition (D). (E) The
quantification of TSP1 staining during the time course of anti-Thyl
disease using a semiquantitative score system from 0 to 4. Complement
depletion with CVF abolished all pathological changes including TSPI
staining at day 5. Data are mean SD. P < 0.01 versus day 0.
- 450 kD
- 205 kD
0 0 5 5 TSP1
Day after ATS injection
Fig. 6. Western blot analysis of unreduced, whole glomemlar lysates for
TSP] using the murine monoclonal antibody TSP A6.]. At day 0 (in
duplicate) very little TSP1 trimer (450 kD) can be detected. At day 5 of
Fig. 5. A linear regression analysis of PCNA and TSP] staining in individual disease (in duplicate) a striking increase in TSP1 protein can be detected.
animals reveals a very high regression coefficient of 0.97, indicating the strong The right lane shows reactivity of the antibody to purified TSPI from
correlation of glomerular TSP] expression with glomerular cell proliferation. human platelets as a positive control.
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Fig. 7. Double labeling of TSP1 protein with PCNA (D), [3HJ thymidine (E) or a-sm actin (A-C) and TSP1 mRNA with a-sm actin (F) on day 5 of anti-Thyl
disease. A typical mesangial pattern of a-sm actin staining in the diseased glomerulus is shown in A (FITC-conjugated in green) and TSP1 protein
staining of the same glomerulus in B (Texas red-conjugated in red). Exposure of both stainings demonstrates that the majority of cells are double labeled
(in orange). Areas which are not double labeled still appear in red or green. A TSP1 positive myofibroblast of Bowman's capsule can also be seen in
these pictures. Double staining for PCNA (grey-black nuclei) and TSP1 protein (brown) (D), as well as TSP1 staining (brown) together with [3H]
thymidine labeling (black grains) (E) reveal that most of the proliferating cells are also expressing TSP1 at day 5 of disease. Combination of in situ
hybridization for TSPI mRNA and immunostaining for a-sm actin (F) identifies the great majority of TSPI mRNA producing cells as mesangial cells
for all time points in disease.
TSP] mRNA is increased in mesangial areas during mesangial ation between days 2 and 7 (peaking at day 5), a phenotypic
proliferative nephritis (anti-Thy] model) change of MCs to a myofibroblast cell type (peaking at day 7) and
This model is associated with an initial complement-dependent mesangial matrix expansion (maximal between days 7 and 14)
mesangiolysis with platelet and macrophage infiltration on days 1 [30].
and 2, followed by a PDGF- and bFGF-dependent MC prolifer- In normal glomeruli TSPI mRNA was minimally present by
-H4.
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Table 1. Comparison of glomerular proliferating cells, PDGF-BB and TSP1 staining and identification of proliferating TSP1 positive cells in
normal rats at day 0, rats with anti-Thyl glomerulonephritis on days 2, 5, 7, and 14 and complement depleted (CVF) rats with anti-Thyl disease at
day 5
Proliferating cells TSP1 positive/PCNA TSP1 negative/PCNA
Glomerular PDGF-BB Glomerular TSP1 per glomerular positive cells per glom. positive cells per glom.
expression (score) expression (score) cross section cross section (in percent cross section (in percent
Day PGF-007 stain TSP1 A 6.1 stain (PCNA-stain) of total PCNA) of total PCNA)
0 0.64 0.24 0 0 0.33 0.16 0 100
2 1.02 0.10" 0.59 0.07" 4.64 1.59" 27 4" 73 4"
5 2.50 015h 2.08 024b 10.75 2.57" 75 6h 25 5"
7 2.53 041" 1.40 012b 7.45 0.87" 49 4" 51 4'
14 1.38 0.41" 0.03 0.02 0.74 0.55 0 100
5 CVF 0.84 0.23 0 0 1.40 0.78 0 100
Data are mean SD.
a Cells were identified as proliferating TSP! positive cells, if the nuclear PCNA staining was completely surrounded by cellular staining for TSPI. Any
other PCNA positive cell was considered TSP1 negative.
"P < 0.01 versus day 0
Northern analysis of RNA from isolated glomeruli and by in situ
hybridization (Figs. 2 and 3 A, B). In rare Bowman's capsules
TSP1 mRNA could be detected by in situ hybridization (not
shown). TSP1 mRNA then rapidly increased, peaking at day 5 (7.7
3.2-fold; Fig. 2), which also correlated with the maximal cell
proliferation. In situ hybridization showed that the primary in-
crease of TSP1 mRNA was in mesangial areas (Fig. 3 C, D) with
some increased expression in the area of Bowman's capsule.
TSP] protein is increased in anti-Thy] disease and correlates with
glomerular cell prolifefation
In normal rats, weak staining of TSP1 protein was detectable in
30% of glomeruli in Bowman's capsule and in the juxtaglomerular
apparatus, but not within the glomerular tuft (Fig. 4A). At day 2,
TSP1-positive platelets could be identified within the glomerulus,
and TSP1-positive cells (cytoplasmic staining) were present near
the juxtaglomerular apparatus (Fig. 4B). By day 5 (Fig. 4C) TSP1
was heavily expressed in a typical mesangial pattern and subsided
quickly thereafter. At days 5 and 7, TSP1 antibody also stained
extracellular matrix (Fig. 4D). By day 14 the increased TSP1
expression had resolved (Fig. 4E). TSP1 expression peaked earlier
(day 5) than PDGF-BB (between days 5 and 7) and completely
paralleled the time course of glomerular cell proliferation, as
assessed by PCNA staining (Table 1). Statistical comparison of
glomerular TSP1 expression with cell proliferation (number of
PCNA-positive cells) in individual animals showed a very close
correlation with a regression (r) value of 0.97 (P < 0.0001; Fig. 5).
The increased TSP1 protein observed by staining was confirmed
by Western blot analysis of whole glomerular lysates (Fig. 6);
minimal TSP1 was detected in normal glomeruli, but the level
increased dramatically in anti-Thyl disease at day 5 (Fig. 6). Two
other anti-TSP antibodies produced identical staining results to
those described. Complement depletion starting prior to disease
induction abolished all pathological changes including TSP1 stain-
ing on day 5 (Fig. 4E).
The source of the increased TSP] protein and TSP] mRNA is
primarily proliferating mesangial cells
Since the correlation of TSP1 staining with glomerular cell
proliferation (PCNA) in our study was striking, we investigated
whether the proliferating (PCNA positive) cells within the gb-
merulus were also expressing TSP1 by double labeling (Table 1).
At the peak of MC proliferation at day 5, the great majority (75
6%) of proliferating cells were TSP1-positive (Fig. 7D). This
result was confirmed by labeling rats with anti-Thy 1 disease at day
5 with [3H] thymidine and immunostaining for TSP1 (Fig. 7E).
Studies were also performed to determine if TSP1 mRNA and
protein were expressed by activated MC. Double staining for
TSP1 and a-sm actin (a marker for activated MC [30]) demon-
strated that the majority of TSP1 positive cells at day 5 expressed
a-sm actin (Fig. 7A-C). A combination of a-sm actin immuno-
staining and in situ hybridization for TSP1 mRNA at all time
points also confirmed that TSP1 mRNA was expressed in glomer-
ular areas associated with prominent a-actin staining (Fig. 7F).
Double staining for ED-i (a marker for monocytes/macrophages)
and TSP1 protein as well as combining ED-i staining with in situ
hybridization for TSP1 mRNA (data not shown) demonstrated
that few ED-i positive cells expressed TSP1 mRNA or protein
(data not shown). Thus, TSP1 protein and mRNA appear to be
predominantly produced by MC in this experimental model of
nephritis.
TSP] protein expression is induced by PDGF and bFGF in vivo
Recently our group demonstrated that PDGF-BB infusion in
normal rats selectively induced glomerular hypercellularity, pri-
marily due to MC proliferation, whereas bFGF was without effect
[241. Re-examination of the same tissue revealed that PDGF-BB
infusion stimulated TSP1 protein expression significantly in these
rats, while bFGF infusion did not (Fig. 8A). The infusion of
PDGF-BB and bFGF together did not increase cell proliferation
or TSP1 expression as compared to PDGF alone.
To evaluate whether preexisting minimal MC damage can
enhance the effects of PDGF or bFGF infusion, rats received a
low dose of anti-Thyl antibody, which by itself did not cause any
significant glomerular cell proliferation or histological changes
[241. Infusion of PDGF or bFGF resulted in a dramatic increase
in TSP1 protein expression (Fig. 8B) in parallel with marked
increases in cell proliferation. PDGF was more potent than bFGF,
and an additive or synergistic effect between PDGF and bFGF
was noted only at day 2 (Fig. 8B), which coincided with the peak
in MC proliferation [24]. Interestingly, in these "subnephrito-
genie" animals without any cytokine infusion a focal and slight
increase in TSP1 staining was observed in 18% of the glomeruli at
day 2, but not at later timepoints (Fig. 8B).
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Fig. 8. Quantification of glomendar immunostaining for TSP] in nonnal
rats (A) or low dose anti- Thy] treated rats (B) after continuous infusion of
equal molarities of either bFGF or PDGF-BB, or both together (bFGF and
PDGF-BB), for (LIi) 2, ) 4, and () 7days. The percentage of glonieruli
showing an increase in TSP1 staining was assessed. Data are mean + SD.
P < 0.05 versus corresponding vehicle-infused groups.
Inhibition of PDGF with anti-PDGF antibody reduces TSP1
protein and mRNA expression in the anti-Thyl model
Anti-PDGF antibody treatment significantly reduced TSPI
protein (by immunostaining) at days 2 and 4 in the anti-Thyl
antibody injection model (Fig. 9A) and markedly reduced TSPI
mRNA expression in glomeruli at day 4 as assessed by in situ
hybridization (Fig. 9B).
Anti-bFGF antibody treatment reduces TSPI expression in the
anti-Thy] model
Anti-bFGF treatment decreased glomerular expression of TSP1
significantly at both day 4 and day 7 in diseased glomeruli, but not
at day 2 (Fig. 9C).
Discussion
TSP1 is a secreted, RGD-containing, extracellular matrix pro-
tein that has been postulated to have a role in platelet aggrega-
tion, monocyte adhesion, apoptosis, and VSMC and MC migra-
tion and proliferation [1]. In vitro studies have shown that TSPI
expression is regulated in MC and VSMC by PDGF [18—20, 36].
Despite the wealth of in vitro data, the mechanisms responsible for
regulation of TSPI in normal and diseased states in v(vo are
unknown. In this paper we provide evidence that TSP1 expression
is induced in proliferating MC in vivo and that it is regulated by
both PDGF and bFGF.
We demonstrate that PDGF [also shown by Kobayashi et al, 20]
and bFGF stimulate TSP1 mRNA expression in cultured MC. The
peak effect was seen six hours after addition of growth factors.
The rapid increase in TSPI mRNA in MC in response to growth
factors suggests that TSP1 is an "immediate-early" response gene,
similiar to the c-fos and c-myc proto-oncogenes [37, 381. Although
the effect of bFGF on TSP1 expression may be direct, bFGF also
stimulates PDGF secretion by MC in culture [391.
Our in vivo studies demonstrate that TSP1 is absent in the
normal rat glomerulus, except for occasional weak staining of
Bowman's capsule (Fig. 4A). In contrast, a dramatic increase in
TSP1 mRNA and protein occurs in experimental mesangial
proliferative nephritis (the anti-Thyl model). Initially, TSPI was
detected in platelets and occurred in cells near the juxtaglomer-
ular apparatus (Fig. 4B). By day 5, when glomerular cell prolifer-
ation peaked (Table 1), the up-regulation of TSP1 protein and
mRNA was maximal and localized to areas of mesangial hyper-
cellularity. The immunostaining pattern of TSP1 was mainly
intracellular at day 2 (Fig. 4B), whereas it appeared to include
extracellular areas at days 5 to 7 (Fig. 4 C, D). By day 14 (and
already by day 10, not shown), however, the increase in TSPI had
resolved. Rats depleted of complement with CVF demonstrated
normal histology and no increased expression of TSP1 mRNA or
protein. This time course of TSP1 expression during anti-Thyl
disease is unusual and unique for an extracellular matrix protein.
TSP1 expression occurs early (day 2), peaks at day 5, and is
transient with expression being absent after day 10. In contrast,
other extracellular matrix proteins, such as collagen I and IV,
laminin, enactin, and heparan sulfate proteoglycan, are expressed
later (day 3), peak between day 5 and 7, and continue to be
present in increased amounts in the mesangial matrix throughout
day 14 [40].
The primary cell type expressing TSP1 protein and TSP1
mRNA is the MC. Alpha-sm actin has been demonstrated as a
specific marker for activated MC [30]. We found predominant
coexpression of a-sm actin and TSP1 mRNA (by in situ hybrid-
ization) or protein (by immunostaining) in the same cells through-
out the proliferative phase of disease (days 2 to 7) (Figs. 7 A-C,
F). TSP1 protein and mRNA were rarely detected in monocytes!
macrophages by double staining for ED-i and TSP1, or by
combining ED-i staining with in situ hybridization of TSP1
mRNA. Low amounts of TSP1 may also be expressed by glomer-
ular endothelial cells, as endothelial cells have been shown to
synthesize TSPI in vitro [29].
The time course of TSP1 expression during disease (days 2 to 7)
paralleled the kinetics of glomerular cell proliferation, as assessed
by immunostaining for PCNA, with a correlation (r value) of 0.97.
TSP1 appears to be a better phenotypic marker of MC prolifer-
ation than PDGF-BB or a-sm actin. We had originally reported
that a-actin is also a marker of MC proliferation [30]. However, its
expression in this experiment peaked at day 7 and remained
elevated until day 14 (data not shown) despite the lack of MC
proliferation at that time. In addition, under certain conditions
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Fig. 9. Glomerular TSPI mRNA and/or TSP] protein expression in anti-
Thy] disease after anti-PDGF (A, B) or anti-bFGF antibody (C) treatment.
Symbols are: (, IL) control; (L:, 1/2) anti-PDGF; () anti-bFGF. Inhibition
of PDGF significantly reduced TSPI protein at days 2 and 4 (A). Reduced
TSPI could also be demonstrated at the mRNA level at day 4 (B).
Anti-bFGF treatment reduced glomerular TSP1 protein expression at day
4 and 7 (C). Data are mean so. *P < 0.01 versus control IgG infused
group.
the expression of a-sm actin by MC can be completely dissociated
from the MC proliferation in vivo [24, 41]. For example, angio-
tensin II infusion in rats will induce marked a-sm actin expression
in MC despite minimal glomerular cell proliferation [41] whereas
PDGF infusion will induce MC proliferation in the absence of
a-sm actin expression [24]. Alpha-sm actin may be a better
phenotypic marker of MC activation as opposed to proliferation
[42], and its role in glomerulonephritis has yet to be defined.
TSP1 expression is regulated by bFGF and/or PDGF in vivo in
both normal and diseased states. First, PDGF infusion induced
TSP1 expression in MC in normal rats and to even a greater
extent in rats primed with low dose ATS, and the degree of
expression correlated with the magnitude of MC proliferation
[24]. Second, anti-PDGF antibody treatment, which we have
previously shown reduces MC proliferation by 60% [25], also
significantly reduces glomerular TSP1 mRNA (by in situ hybrid-
ization) and TSPI protein (by immunostaining) in anti-Thyl
disease. Third, bFGF was able to induce MC proliferation [24]
and TSP1 expression in rats with low dose ATS. Finally, anti-
bFGF antibody treatment in the anti-Thyl model, which we have
recently shown inhibits MC proliferation and a-sm actin expres-
sion [43], also reduces TSP1 expression.
An additional observation was that low dose anti-Thyl antibody
was able, in itself, to induce a transient and low level expression of
TSP1. We have also previously reported that low dose anti-Thyl
may act to "prime" the MC to become more responsive to growth
factors, since PDGF or bFGF infusion in rats injected with low
dose ATS develop a much more severe proliferative response
than control rats with PDGF or bFGF infusion. It is possible that
the mechanism by which low dose ATS "primes" the MC to
become more responsive to PDGF involves an induction of TSPI.
The function of TSP1 in vivo remains unknown. In vitro studies
suggest a role in cell proliferation [191, cell migration [17], TGF-/3
activation [44, 45] and apoptosis [16, 46]. Our studies are most
consistent with a role of TSP1 in MC proliferation in vivo. The
finding that TSPI was tightly linked to MC proliferation and
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PDGF expression is of interest, in particular, given the recent
studies by Marinides, Suchard and Mookerjee [19] documenting a
close interaction of PDGF and TSP1 in mediating MC prolifera-
tion in vitro.
In conclusion, this study demonstrates that mesangial prolifer-
ative nephritis is associated with de novo TSPI mRNA and protein
expression. The primary source of the TSP1 is the proliferating
mesangial cell. Finally, this study provides the first evidence that
TSPI expression in vivo is regulated by the growth factors PDGF
and bFGF.
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